BioCardia, Inc.
BCDA Healthcare Biotechnology
BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024. In the quarter to June 2026, EPS grew 67.5% and free cash flow fell 5.15%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow BCDA
BioCardia, Inc. (BCDA) EV/Sales
As of 16 October 2026, BioCardia, Inc. (BCDA) trades at a EV/Sales of 30.2×. Over the past ten years it has ranged from −12.4× (October 2016) to 606× (July 2017); the current reading is higher than 45% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 27.4× | 23.43% |
| FY2024 | 22.2× | (43.56%) |
| FY2023 | 39.4× | 43.78% |
| FY2022 | 27.4× | 7.43% |
| FY2021 | 25.5× | (81.07%) |
| FY2020 | 135× | 344.83% |
| FY2019 | 30.3× | (59.23%) |
| FY2018 | 74.2× | (64.13%) |
| FY2017 | 207× | 29.85% |
| FY2016 | 159× | 3,881.39% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | 23.6× | (26.48%) |
| Mar 2024 | 32.1× | (18.54%) |
| Dec 2023 | 39.4× | 67.96% |
| Sep 2023 | 23.4× | (82.22%) |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | −66.3× |
| LPCN Lipocine Inc. compare | −5.2× |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| RVLP RVL Pharmaceuticals PLC compare | 1.0× |
| CLVSQ Clovis Oncology, Inc. compare | 3.1× |
| CNSY Cerenome, Inc. compare | 3.3× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| TVRD Tvardi Therapeutics, Inc. compare | 4.8× |
| BCDA BioCardia, Inc. | 30.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)